Sharon Mates - Apr 24, 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Chairman and CEO, Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Apr 24, 2024
Transactions value $
$345,618
Form type
4
Date filed
4/25/2024, 05:08 PM
Previous filing
Mar 11, 2024
Next filing
Aug 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $146K +8.64K +0.82% $16.86 1.06M Apr 24, 2024 Direct
transaction ITCI Common Stock Options Exercise $200K +11.4K +1.07% $17.57 1.07M Apr 24, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -8.64K -100% $0.00* 0 Apr 24, 2024 Common Stock 8.64K $16.86 Direct F1
transaction ITCI Stock Option (right to buy) Options Exercise $0 -11.4K -4.98% $0.00 217K Apr 24, 2024 Common Stock 11.4K $17.57 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested.
F2 This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested.